Pacific Biosciences of California, Inc.
PACB
$1.38
$0.129.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.42% | -4.27% | -32.79% | -28.23% | -24.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.42% | -4.27% | -32.79% | -28.23% | -24.30% |
| Cost of Revenue | -5.95% | 14.99% | -28.63% | -28.83% | -16.94% |
| Gross Profit | 55.70% | -44.22% | -45.44% | -26.99% | -39.20% |
| SG&A Expenses | -21.15% | -8.19% | 21.84% | -15.16% | 13.07% |
| Depreciation & Amortization | -85.17% | 5,249.50% | 0.01% | 640.54% | 3,643.17% |
| Other Operating Expenses | -- | -- | -70.95% | -- | -- |
| Total Operating Expenses | -28.10% | 290.70% | -11.15% | -25.87% | -0.94% |
| Operating Income | 45.09% | -431.28% | -3.46% | 24.09% | -14.67% |
| Income Before Tax | 75.83% | -445.39% | 103.25% | 21.72% | -148.19% |
| Income Tax Expenses | -- | -- | 144.01% | -- | -- |
| Earnings from Continuing Operations | 75.81% | -445.01% | 102.89% | 9.19% | -148.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.81% | -445.01% | 102.89% | 9.19% | -148.19% |
| EBIT | 45.09% | -431.28% | -3.46% | 24.09% | -14.67% |
| EBITDA | 42.28% | 14.33% | -4.08% | 35.71% | -4.63% |
| EPS Basic | 78.04% | -394.93% | 102.74% | 15.14% | -127.82% |
| Normalized Basic EPS | 52.56% | -376.47% | -0.15% | 28.55% | -11.73% |
| EPS Diluted | 78.13% | -396.55% | 102.65% | 15.14% | -128.57% |
| Normalized Diluted EPS | 52.56% | -376.47% | 7.65% | 28.55% | -11.73% |
| Average Basic Shares Outstanding | 10.20% | 10.12% | 5.94% | 7.03% | 8.92% |
| Average Diluted Shares Outstanding | 10.20% | 10.12% | 14.89% | 7.03% | 8.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |